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ABSTRACT 
Aim 
To study the association of high sensitivity troponin T (hsTnT) with incident heart failure, 
and implications for its use in prediction models. 
Methods and Results 
The British Regional Heart Study of 3852 men aged 60-79 without baseline HF (3165 without 
baseline CHD) was followed up for a median of 12.6 years, during which 295 incident cases 
of HF occurred (7.7%). A 1 standard deviation increase in log-transformed hsTnT was 
associated with a higher risk of incident HF after adjusting for classical risk factors (HR 1.58 
[95% CI 1.42, 1.77]) and after additional adjustment for NT-proBNP (HR 1.34 [95% CI 1.19, 
1.52]). The strength of the association between hsTnT and incident HF did not differ by 
strata of other risk factors. A hsTnT concentration of <5ng/L had a sensitivity of 99.7% 
(95%CI 98.1-99.9%) and a specificity of 3.4% (95%CI 2.8%-4.0%). A risk prediction model 
including classic risk factors and NT-proBNP yielded a c-index of 0.791, but addition of hsTnT 
did not further improve prediction (p=0.28).  
Conclusions 
Elevated hsTnT is consistently associated with risk of HF in older men. HF rarely occurs over 
12 years when baseline hsTnT is below the limit of detection.  hsTnT measurement, 
however, does not improve HF prediction in a model already containing NT proBNP. 
Key words: Risk prediction; heart failure; biomarkers; troponin T;  
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Introduction 
The lifetime risk of developing heart failure (HF) of a person aged over 40 years in the 
general population is estimated at 20% and, although therapies for HF are improving, once 
diagnosed 14% of patients die in the first six months. [1,2] The etiology of HF varies from 
country to country, although the majority of cases are attributed to hypertension and 
coronary artery disease. [3] As such, it is well understood that onset of HF is a common 
occurrence after clinically diagnosed myocardial infarction. [4] However, it is possible that 
recurrent subclinical episodes of cardiac ischemia and cardiomyocyte necrosis lead to heart 
failure. [5]  
 
Circulating cardiac troponin levels are excellent biomarkers of myocardial injury, including 
ischemia. [6,7] As such, several studies have used high sensitivity troponin T (hsTnT) or high 
sensitivity troponin I (hsTnI) assays as a proxy for subclinical myocardial damage in 
investigating causes of HF. [8–12] However, it is not clear from the existing literature what 
information troponin measurement adds to N-terminal pro B-type natriuretic peptide (NT 
proBNP). NT-proBNP integrates information about cardiac loading, structure and function, 
the heart rhythm, renal function and possibly other neurohumoral pathways. Since 
natriuretic peptides are increasingly part of the clinical definition of HF, [13] and are 
routinely measured during the diagnostic evaluation of patients with suspected HF, NT 
proBNP is a strong candidate biomarker for prediction models in people without HF. It is 
also possible that troponin will also be valuable in such predictive models. A key question is 
not only whether continuous troponin levels predict HF, but also whether low troponin 
levels, indicating an absence of myocardial injury, preclude occurrence of HF. 
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We therefore used the British Regional Heart study to test the hypothesis that hsTnT is 
associated with risk of incident HF in older men with and without clinical evidence of 
baseline CHD, adjusting for incident CHD during follow-up. We also examined whether the 
measurement of hsTnT usefully predicts risk of incident heart failure beyond NT-proBNP. 
 
Materials and Methods 
British Regional Heart Study 
The British Regional Heart Study was a socioeconomically representative prospective study 
of 7735 men aged 40-59 years and of predominantly white European ethnicity (>99%), 
drawn from one general practice in each of 24 British towns, who were screened between 
1978 and 1980. [14] In 1998-2000, surviving men aged 60-79 years were invited for a 20th 
year follow-up examination, on which these analyses are based. [15,16] Ethical approval was 
obtained from all relevant local research ethics committees, and informed consent has been 
obtained from the subjects. Follow-up was possible for 99% of the cohort. All men 
completed a mailed questionnaire providing information on their lifestyle and medical 
history, had a physical examination, and provided a fasting blood sample. Physical activity, 
alcohol consumption and an index of socioeconomic deprivation were derived and coded as 
detailed elsewhere. [17] Twelve-lead electrocardiograms were recorded using a Siemens 
Sicard 460 instrument and were analyzed using Minnesota Coding definitions at the 
University of Glasgow ECG core laboratory. Atrial fibrillation was defined according to 
Minnesota Codes 8.3.1 and 8.3.3 on baseline ECG. The men were asked whether a doctor 
had ever told them that they had MI, HF, or stroke; details of their medications including 
use of statins were recorded at the examination. Predicted glomerular filtration rate (eGFR) 
was estimated from serum creatinine; eGFR = 186 x (creatinine)-1.154 x (Age)-0.203.  
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In all, 4252 men (77% of survivors) attended the 1998 to 2000 examination; 130 men who 
experienced heart failure before the baseline examination were excluded; 79 men with 
missing information on history of MI or angina were also excluded; and an additional 191 
with a missing hsTnT measurement were excluded, leaving 3852 men included in the 
analysis.  
 
Baseline CHD was defined as previous self-reported, doctor-diagnosed, MI or angina, or MI 
identified during review of medical records as part of the prospective study; in this way, 687 
men were defined as having evidence of CHD at baseline.  
 
Evidence of HF was obtained by reports from GPs supplemented by biennial reviews of 
medical records (including correspondence). Incident HF was based on a confirmed doctor 
diagnosis of HF from primary care records and where possible, verified using details of 
available clinical information from primary and secondary care records, as well as from 
death certificates (ICD-9 code 428). [16] 
 
Biomarker measurement 
NT-proBNP and hsTnT were measured in plasma samples from both studies on an 
automated clinically validated immunoassay analyser (e411, Roche Diagnostics, Burgess Hill, 
UK) using the manufacturers calibrators and quality control reagents. The limit of detection 
was 5ng/L for NT-proBNP, and limit of blank was 3ng/L for hsTnT. We defined “low” hsTnT 
using the manufacturer’s limit of detection (5ng/L). Quality control materials over two levels 
for each biomarker ran between 4.4% and 7.7%.  
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Statistics 
Eligible men were divided into equal tertiles based on the hsTnT distribution. Skewed 
continuous variables were log-transformed to approximate normality for parametric tests. 
Comparisons of baseline characteristics between the HF outcome groups (stratified by 
baseline CHD status) were performed using the χ2 test for categorical variables and t-test for 
continuous variables. 95% confidence intervals for single proportions were derived using 
Jeffrey’s method.  
 
Kaplan –Meier curves and the log-rank test were used to evaluate differences in HF rates for 
the hsTnT tertiles. Multiple imputation using chained equations was used to generate 10 
datasets with complete data [18]. The imputation model included hsTnT, age, CVD, 
diabetes, incident heart failure (none missing), smoking (4 missing), index of deprivation (6 
missing), atrial fibrillation (9 missing), heart rate (10 missing), systolic blood pressure (17 
missing), body mass index (17 missing), C-reactive protein (31 missing), eGFR (35 missing), 
total cholesterol (38 missing), glucose (39 missing), FEV1 (40 missing), blood pressure 
medications (49 missing), alcohol use (57 missing), HDL-cholesterol (61 missing), physical 
activity (138 missing), and NT-proBNP (272 missing).  Cox proportional hazards models were 
generated using the mi estimate command in STATA. The hazard ratio (and 95% confidence 
intervals) of incident heart failure per a one standard deviation increase in log-transformed 
hsTnT was estimated using these models. Models adjusted for classical risk factors with the 
maximally adjusted model including the variables; age, smoking, total cholesterol, HDl-
cholesterol, systolic blood pressure, index of multiple deprivation (IMD), BMI, any diabetes, 
eGFR, blood pressure medication, statin use, heart rate, physical activity, FEV1, alcohol 
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consumption, CRP and NT-proBNP. Models also included a time-varying term adjusting for 
non-fatal MI that occurred during the follow-up. Maximally adjusted models were also 
tested for evidence of interaction, stratified by baseline covariates of interest. The 
assumption of a linear relationship between hsTnT and risk of heart failure was supported 
by restricted cubic spline analysis. 
 
To test clinical prediction of incident HF, C-indices were calculated in the imputed datasets 
accounting for censoring, using a range of different prediction strategies (with or without 
hsTnT). Prediction models included: Model (A) age, baseline CHD, cholesterol, HDL 
cholesterol, systolic blood pressure, IMD, BMI, smoking, diabetes, eGFR, BP medication, 
statin use, heart rate, glucose, physical activity, FEV1, alcohol use, atrial fibrillation; Model 
(B) model A plus NT-proBNP; Model (C) model B plus hsTnT; Model (D) Age and NT-proBNP 
only. Increased concordance was tested comparing the C-index each model to every other.  
 
The C statistic has been criticised for insensitivities to changes in clinical decisions across 
treatment thresholds defined by risk prediction. The categorical net reclassification index 
(NRI) estimates correct changes in clinical classification across risk thresholds. However, risk 
scores thresholds are currently not used to make treatment decisions to prevent heart 
failure. Therefore, we used a continuous net reclassification index (NRI), to compare model 
C compared to model B in one imputed dataset. NRI is based on improvements in 
classification across integer % risk thresholds, thus avoid making arbitrary decisions about 
defining clinically relevant risk categories. [19] We also calculated the integrated 
discrimination improvement index (IDI), a category free comparative measure of the clinical 
validity of a new risk score. [20] 
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All analyses were performed in STATA (version 14.2) and R (version 3.3.1, using the 
survIDINRI package and 5000 bootstrap samples to generate confidence intervals for the 
NRI and IDI). 
 
Results 
Classical risk factors 
During a median follow-up period of 12.6 years (IQR 7.9-13.4 years), there were 295 
incident cases of HF in the whole cohort (n=3852; incidence 7.7%), including 201 incident 
cases (6.4%) in those without baseline CHD (n=3165), and 94 incident cases (13.7%) in those 
with baseline CHD (n=687) (p<0.001). Those who experienced HF during follow-up were also 
generally older, had higher BMI and waist circumference and were more likely to have 
diabetes, had lower FEV1 and eGFR, had a higher heart rate, were more likely to be on 
blood pressure lowering medication and to have atrial fibrillation and a higher CRP (Table 1). 
hsTnT was slightly higher in those with baseline CHD compared to those without (median 
and interquartile range: 12.9 (9.9-18.2) vs. 11.4ng/L (8.6-15.6) , p<0.001). NT-proBNP was 
also higher in those with clinical evidence of baseline CHD compared to those without 
(median and interquartile range: 180ng/L (88-416) vs.79ng/L (41-158), p<0.001). 
 
hsTnT and incident HF 
Kaplan-Meier curves show that over the follow-up time, baseline hsTnT concentration (as 
thirds of the distribution) was strongly associated with risk of incident HF in both those with 
and without baseline CHD (log rank p<0.001 for both) (Fig 1). 
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In adjusted models, the association of log transformed hsTnT with heart failure was linear 
(graphical abstract uses 10ng/L, approximately the median hsTnT, as the referent). In all 
participants, a 1 standard deviation higher log hsTnT was associated with a 58% (95% CI 
42%, 77%) higher risk of HF after adjusting for classical risk factors (model 3, Table 2), and 
this was attenuated to a 34% higher risk (95% CI 19%, 52%) after adjusting for NT-proBNP as 
well (model 4). A test for interaction between the risk of HF associated with baseline hsTnT 
concentration and baseline CHD status was not significant p=0.32, Fig 2). Indeed, there was 
no evidence that level of any risk factor modified the association between hsTnT and risk of 
HF (Fig 2).  
 
Prediction of HF 
Of the 121 people with a baseline hsTnT <5ng/L (the assay limit of detection), only 1 
developed new onset HF (0.8%; 95%CI 0%-3.8%), compared with 294 of the 3731 with a 
detectable hsTnT (7.9%; 95%CI 7.1-8.8%). This corresponds to a sensitivity of 99.7% (95%CI 
98.1-99.9%) anda specificity of 3.4% (95%CI 2.8%-4.0%). Only 35 participants had an NT-
proBNP below the limit of detection (5pg/ml), and none developed heart failure during 
follow-up. 
 
A HF risk score based on classical risk factors (without sex or race) yielded a c-index of 0.730 
(model A, Table 3). Addition of NT-proBNP improved the c-index substantially to 0.791 
(model B). However, further addition of hsTnT (Model C) did not further improve prediction 
(c-index 0.794). A model based on age and NT-proBNP only (model D) yielded a c-index of 
0.757 and was almost as good at discriminating HF events as any of the other more complex 
models. 
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Using other prediction metrics, adding hsTnT to a model containing NT-proBNP (Model C vs. 
B) did not improve the continuous net reclassification index (+6.7%; 95%CI -4.9, 16.0%; 
p=0.26) although there was a slight improvement in the integrated discrimination index 
(+0.013; 95%CI; 0.003, 0.026; p=0.006). Data were similar when stratified by baseline CHD 
(data not shown). 
 
Discussion 
In this cohort of older British men, hsTnT was consistently strongly associated with incident 
HF, suggesting that subclinical myocardial damage may be an important risk factor for HF, 
even in individuals without diagnosed CHD. HF rarely occurred during 12.6 years of follow-
up (0.8% incidence; 95%CI 0%-3.8%) in men who had a baseline hsTnT below the limit of 
detection (5ng/L). As such, these data raise mechanistic questions regarding the source of 
troponin elevation in apparently healthy men, and as to how pathologies that raise troponin 
might be associated with increased HF risk.  Although useful in predicting HF when added to 
conventional risk factors, TnT did not improve HF prediction when added to NT-proBNP. 
 
Heart failure prediction 
One of the reasons NT-proBNP is such an attractive and powerful biomarker in CVD 
prediction in general [17,21,22] is that it integrates information from several important 
pathophysiological pathways. As well as reflecting cardiac overload, NT-proBNP is also a 
marker of myocardial ischemia, therefore overlapping with troponin. [23,24] Circulating 
levels of both NT-proBNP and hsTnT probably also reflect renal function. [25] Despite this, 
we still found a moderate association between hsTnT and HF, even after adjusting for classic 
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risk factors and NT-proBNP. However, once NT-proBNP is included in a model for HF 
prediction, the baseline C-statistic is already high (0.79), and it is therefore difficult to 
improve upon. Data from the ARIC study showed that when TnT was added to a range of 
classical risk factors plus NT-proBNP, the c-index for HF prediction was improved statistically 
significantly, but only clinically modestly (by +0.014 in men and +0.012 in women). [9] 
Although the present study is smaller in size, our data broadly agree with those of ARIC: if 
hsTnT does predict HF beyond NT-proBNP, the discrimination gained is very moderate. Our 
data also advance findings from studies from patients with established acute and chronic 
heart failure. For instance, in chronic heart failure patients in the Reduction of Events by 
Darbepoetin Alfa in Heart Failure (RED-HF) trial, among a range of cardiac biomarkers only 
hsTnT added to NT-proBNP in the prediction of adverse outcome [26]. In the Multicentre 
Australian Risk Algorithm To predict Heart failure readmission (MARATHON) study, 
comprising patients hospitalized with preserved or reduced ejection fraction heart failure, 
elevated troponin I predicted 30-day readmission to hospital or death, individually and as 
part of a panel of variables [27]. Therefore, elevated troponin appears to be a predictor of 
adverse outcomes in the pre-symptomatic, chronic and acute phases of heart failure. 
 
Mechanisms linking troponin and heart failure 
In line with these being older men, the median baseline hsTnT level in this cohort was 
approximately 12ng/L (the 99th percentile in the healthy population is 14ng/L), and was only 
slightly higher in those with clinically identified baseline CHD. CHD is the most obvious cause 
of elevated troponin, although only a minority of our participants had diagnosed CHD at 
baseline.  However, even in the absence of a diagnosis of CHD, the prevalence of subclinical 
coronary disease was probably high in the older British men we studied. However, even in 
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the absence of a diagnosis of CHD, the prevalence of subclinical coronary disease was 
probably high in the older British men we studied. In addition, other potentially 
undiagnosed cardiac conditions such as left ventricular hypertrophy and atrial fibrillation 
may cause myocardial ischemia. Hypertension, diabetes and chronic kidney disease (which 
frequently coexist) lead to the development of left ventricular hypertrophy and atrial 
fibrillation, as well as coronary microvascular dysfunction which may also raise troponin. 
Hypertension, diabetes and chronic kidney disease, left ventricular hypertrophy, atrial 
fibrillation and coronary microvascular dysfunction are also predictors (and those measured 
in this study) precursors of heart failure. Moreover, those developing HF had a higher 
baseline NT-proBNP concentration, suggesting pre-existing myocardial and/or renal 
dysfunction. Other non-cardiac pathologies including chronic inflammatory disorders are 
also associated with myocardial injury and the higher baseline CRP in individuals 
experiencing incident HF is consistent with this pathophysiological connection as well. [28] 
Thus, there are mechanisms that might explain why troponin is not only associated with 
incident heart failure in those with diagnosed CHD. Many of these factors were taken into 
account in our statistical analysis. Future studies should investigate specifically the ability of 
troponin measurements to predict onset of non-ischaemic dilated cardiomyopathy. 
 
It may be possible to detect subclinical myocardial injury early and intervene to reduce the 
risk of heart failure. This might be achieved using measurement of troponin, NT-proBNP or 
both to diagnose such patients and thereby target therapy to those at highest risk of HF. 
Interventions that might be effective include antihypertensive therapies, anti-ischemic 
therapies, lipid-lowering treatments, anti-thrombotic therapy and, possibly, drugs improving 
metabolic status (e.g. treatments for diabetes and obesity). The small but statistically 
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significant effect of statins in reducing the risk of incident heart failure, independently of 
myocardial infarction, is consistent with this hypothesis. [29] A recent example of a 
hypotensive agent which also lowers troponin is sacubitril/valsartan (formerly LCZ696).[30] 
Prevention of myocardial injury to reduce risk of heart failure in later life is therefore an 
important public health aim, in the same way that reduction in acute myocardial infarction 
and stroke is. 
 
Study strengths and limitations 
Strengths of the study include the prospective nature of the data and the relatively large 
size of the study with a long follow-up period. We used a high quality validated clinical assay 
in routine use in clinical biochemistry departments to measure both NT-proBNP and hsTnT. 
Weaknesses include that current findings are based on doctor-diagnosed HF, and although 
diagnoses were usually supported by evidence from hospital investigations, there is likely to 
be some outcome misclassification, including under-reporting of incident heart failure. 
Because we did not have echocardiographic data, we were unable to differentiate incident 
HF with reduced ejection fraction from HF with preserved ejection fraction. Similarly, 
routine coronary angiography was not performed in common with most cohort studies. 
These limitations mean that we cannot be sure to what extent information gained from 
measuring hsTnT overlaps with information that have might been available had other 
diagnostic investigations been performed.  However, a potential use of cardiac biomarkers is 
to select the most appropriate patients in which to carry out these investigations. [31,32] 
Finally, we studied older male survivors from a socioeconomically representative general 
cohort study, but participants were a predominantly white population of European origin, so 
that the results cannot be generalised directly to women, or to younger individuals or other 
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ethnic groups. However, additional studies such as ARIC (aged 45-64 at baseline) [9] also 
demonstrate an association of hsTnT with incident heart failure in both men and women in 
an ethnically diverse cohort, providing external validity. 
 
Conclusion 
Although NT-proBNP is the most powerful predictor of HF, even low grade elevation in 
hsTnT is consistently associated with a higher risk of HF in older men, and HF rarely occurs 
when hsTnT is near the limit of detection. Interventions to prevent myocardial injury may 
mitigate risk of HF in later life. 
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Figure legends 
Figure 1 
Kaplan Meier curves illustrating event free survival from HF by tertiles of hsTnT in a) those 
without baseline CHD b) those with baseline CHD. Blue curves are the lowest 
tertile(≤9.7ng/L), red the middle tertile (9.8-14.2ng/L), and green the top tertile (≥14.3ng/L). 
Cutoffs are defined from the whole cohort. 
 
Figure 2 
Hazard ratio for heart failure per 1 SD increase in hsTnT, stratified by a range of other risk 
factors. P-values are tests for interaction comparing the effect of hsTnT in stratified groups 
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Table 1 Distribution of risk factors at baseline comparing those who experience HF during follow-up to those who do not 
Risk factor No incident heart failure 
(n=3557) 
Incident heart failure (n=295)  
Age (years) 68.5 (5.5) 70.5 (5.4) p<0.001 
BMI 26.8 (3.6) 27.8 (3.9) p<0.001 
Waist Circ (cm) 96.7 (10.4) 99.7 (11.2) p<0.001 
Smoking 
Never 
Ex 
Current 
 
1048 (29.5%) 
2039 (57.4%) 
466 (13.1%) 
 
79 (26.8%) 
181 (61.4%) 
35 (11.9%) 
p=0.42 
FEV1 2.62 (0.65) 2.40 (0.68) p<0.001 
SBP 149.1 (24.0) 152.2 (25.2) p=0.04 
DBP 85.4 (11.1) 84.8 (11.0) p=0.43 
Heart rate 65.5 (12.5) 67.6 (13.7) p=0.006 
Total Chol 6.02 (1.07) 5.90 (1.12) p=0.08 
HDL Chol 1.32 (0.34) 1.29 (0.34) p=0.14 
Glucose 5.99 (1.79) 6.30 (2.55) p=0.006 
Physical activity   p=0.03 
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Inactive 
Occasional-light 
Moderate-vigorous 
360 (10.5%) 
1424 (41.5%) 
1645 (48.0%) 
35 (12.3%) 
127 (44.6%) 
123 (43.2%) 
Alcohol 
None 
Occasional/light 
Moderate-Heavy 
 
347 (9.9%) 
2469 (70.5%) 
688 (19.6%) 
 
32 (11.2%) 
205 (69.7%) 
54 (19.1%) 
p=0.79 
Diabetes 232 (6.5%) 33 (11.2%) p=0.002 
Atrial fibrillation 105 (3.0%) 30 (10.2%) p<0.001 
Statin 212 (6.0%) 25 (8.5%) p=0.084 
Blood pressure med 1056 (30.1%) 139 (47.8%) p<0.001 
Index of multiple deprivation (IMD) 20.2 (14.7) 20.6 (14.7) p=0.66 
eGFR 72.8 (12.6) 70.1 (13.4) p<0.001 
CRP 1.54 [0.81, 3.33] 2.16 [1.04, 4.18] p<0.001 
NT-proBNP 85 [44, 173] 231 [102, 577] p<0.001 
hsTnT 11.5 [8.7, 15.6] 15.5 [11.0, 20.1] p<0.001 
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Table 2 Associations of hsTnT  (per SD increase on log scale) with HF 
Study/events N 
(n events) 
Model 1 Model 2 Model 3 Model 4 
  HR 
(95% CI) 
p-value HR 
(95% CI) 
p-value HR 
(95% CI) 
p-value HR 
(95% CI) 
p-value 
All participants 3852 
(295) 
1.81 
(1.66, 1.97) 
<0.001 1.64 
(1.47, 1.82) 
<0.001 1.58 
(1.42, 1.77) 
<0.001 1.34 
(1.19, 1.52) 
<0.001 
          
Participants without 
baseline CHD 
3165 
(201) 
1.76 
(1.57, 1.96) 
<0.001 1.59 
(1.40, 1.81) 
<0.001 1.51 
(1.32, 1.74) 
<0.001 1.33 
(1.15, 1.53) 
<0.001 
          
Participants with baseline 
CHD 
687 
(94) 
1.82 
(1.55, 2.12) 
<0.001 1.79 
(1.47, 2.18) 
<0.001 1.83 
(1.48, 2.26) 
<0.001 1.44 
(1.13, 1.84) 
0.001 
Model 1 unadjusted 
Model 2 adjusted for: age, total cholesterol, HDL cholesterol, systolic blood pressure, IMD, BMI, smoking, diabetes, eGFR, BP medication use, statin 
use, and MI that occurred during follow-up  
Model 3 additionally adjusted for:  heart rate, glucose, physical activity, FEV1, alcohol use, atrial fibrillation, CRP 
Model 4: additionally adjusted for: NT-proBNP 
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Table 3 Prediction of heart failure in those without baseline CHD: C-statistics matrix comparing various models with and 
without hsTnT (n=3852) 
Model C-index Vs Model A Vs Model B Vs  Model C 
Model A 
Classical risk factors* 
0.730  
(0.701, 0.759) 
   
Model B 
Classical risk factors plus NT-proBNP 
0.791 
(0.766, 0.816) 
+0.061 
(0.039, 0.082) 
p<0.001 
  
Model C 
Classical risk factors plus NT-proBNP and hsTnT 
0.794 
(0.769, 0.819) 
+0.064 
(0.043, 0.086) 
p<0.001 
+0.004 
(-0.003, 0.010) 
p=0.28 
 
Model D 
Age and NT-proBNP 
0.757 
(0.729, 0.785) 
+0.027 
(-0.004, 0.058) 
p=0.09 
-0.034 
(-0.050, -0.018) 
p<0.001 
-0.037 
(-0.055, -0.020) 
p<0.001 
* age, total cholesterol, HDL cholesterol, systolic blood pressure, IMD, BMI, smoking, diabetes, eGFR, BP medication use, statin use, heart rate, glucose, 
physical activity, FEV1, alcohol use, atrial fibrillation, and baseline CVD 
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